Novo Nordisk Stock: Buy And Forget (NYSE:NVO)

Group 1 - Novo Nordisk A/S (NVO) shareholders have experienced a significant decline in stock value in 2025 due to increased competition and pressure from the U.S. government to lower drug prices [1] - The company has also provided a pared-back financial outlook, contributing to the negative sentiment among investors [1] Group 2 - The article emphasizes the importance of conducting due diligence before making investment decisions, highlighting that past performance does not guarantee future results [2]